Fig. 3From: ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignanciesStratified hazard ratio of cancer progression for ALDH2*2 carriers estimated from a 6-month observation. Reference = ALDH2*1/*1 carriers. Hazard ratio and 95% confidence interval (error bar) were estimated by Cox proportional hazard model adjusted for covariates used in Model 4 in Table 4. PD-L1; programmed death-ligand 1, EGFR; epidermal growth factor receptor. Cases with unknown TNM classification (N = 29), unknown PD-L1 (+) ratio in cancer tissue (N = 15), and unknown EGFR mutation in cancer tissue (N = 16) were excludedBack to article page